Evaluating pharmacist preparedness to administer long acting injectable antiretroviral treatments in the community pharmacy setting

Monday, June 15th 2020

10:00 AM - 11:30 AM

PAST EVENT

The Integrase strand transfer inhibitor cabotegravir (CAB) and the non-nucleotide reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) are being coformulated as a long-acting injectable antiretroviral therapy (LAI-ART) option, which can be administered intramuscularly in the gluteus medius every 4 weeks. LAI-ART would replace a patient’s oral antiretroviral therapy (ART), decreasing pill burden and increasing the possibility of improved medication adherence. Medication adherence is critical for patients living with Human Immunodeficiency Virus (HIV) to suppress the viral load and preserve immune function.The primary objective of the study is to evaluate the preparedness of pharmacists, who have experience administering intramuscular (IM) treatment, to inject LAI-ART in the community pharmacy setting. The secondary objective is to identify preferred training methods for these pharmacists. As a result a total of 127 survey responses were evaluated for this research. 57.3% of pharmacists felt prepared to administer LAI-ART in the community setting. Patient care pharmacists and residents felt more prepared to administer LAI-ART compared to pharmacy managers and staff pharmacists (P-value = 0.047). 30.3% of pharmacists strongly disagreed to being adequately trained to administer IM ventrogluteal (VG) injections. 97.1 % of pharmacists prefer either live sessions or written training.

Objectives

  • Define Integrase strand transfer inhibitor cabotegravir (CAB) and the non-nucleotide reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV)
  • Increase pharmacist preparedness to administer long acting injectable antiretroviral treatments in the community pharmacy setting
  • Communicate, in relatable language, results of the study. 

 

Presenter

Disha Soni, PharmD

PGY-1 Community-Based Pharmacy Resident

Dr. Disha Soni is a PGY-1 community based pharmacy resident at Acme Pharmacy and adjunct faculty at Temple University School of Pharmacy. She has received her Doctor of Pharmacy and minor in Pharmaceutical Healthcare and Business from Philadelphia College of Pharmacy in 2019.  She is actively involved in the implementation and enhancement of clinical services including immunizations, medication therapy management services, disease state management and medication administration programs. She has conducted her research in evaluating pharmacist preparedness in administering long-acting injectable antiretroviral therapy in the community setting.

 

 

Location Details

Webinar

Spotlight On

Karam Mounzer, MD

Dr. Mounzer identified two major gaps in the care of patients with HIV/hepatitis C (HCV) co-infection, and the complexity of multidrug-resistant HIV treatment. He is involved with many clinical trials focusing on drug development and better understanding of HIV immunopathogenesis with the Wistar Institute. He is involved in teaching and mentoring.

Learn More about Spotlight On
Dr. Karam Mounzer

Dr. Mario Cruz

Dr. Mario CruzDr. Cruz is a board certified pediatrician who serves as the Medical Director for our Pediatrics and Adolescent Health Center. He has presented and/or published in the fields of community violence and domestic violence prevention, quality improvement, behavioral health, curriculum development and mentorship. In 2019 he received the Greater Philadelphia Social Innovation Award for Innovations in Healthcare.


Translate »